EPIVON FILM-COATED TABLETS 1000MG

PHARMATHEN S.A. (GREECE)🇸🇬 Health Sciences Authority

Approval Date: Nov 29, 2013
Approval ID: 286cc768eefcee5b
Company: PHARMATHEN S.A. (GREECE)
Type: Therapeutic

Approval Details

Approval Id: 286cc768eefcee5b
Drug Name: EPIVON FILM-COATED TABLETS 1000MG
Product Name: EPIVON FILM-COATED TABLETS 1000MG
Approval Number: SIN14449P
Approval Date: 2013-11-29
Registrant: NOVEM PHARMA PRIVATE LIMITED
Licence Holder: NOVEM PHARMA PRIVATE LIMITED
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: TABLET, FILM COATED
Dosage: 4.2 Posology and method of administration Posology Monotherapy for adults and adolescents from 16 years of age The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily. Add-on therapy for adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks. Special populations Elderly (65 years and older) Adjustment of the dose is recommended in elderly patients with compromised renal function (see “Renal impairment” below). Renal impairment The daily dose must be individualised according to renal function (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in ml/min is needed. The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighing 50 kg or more, using the following formula: <img src="/TGIF/Epivon-Formula1.png" alt="Epivon Dosage Formula 1" /> Then CLcr is adjusted for body surface area (BSA) as follows: <img src="/TGIF/Epivon-Formula2.png" alt="Epivon Dosage Formula 2" /> Dosing adjustment for adult and adolescent patients weighing more than 50 kg with impaired renal function <img src="/TGIF/Epivon-Table1.png" alt="Epivon Dosage Table 1" /> For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. This recommendation is based on a study in adult patients with renal impairment. Hepatic impairment No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. Therefore, a 50 % reduction of the daily maintenance dose is recommended when the creatinine clearance is < 60 ml/min/1.73 m2 (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Paediatric population The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose. The tablet formulation is not adapted for use in children under the age of 6 years. An oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases an oral solution should be used. Monotherapy The safety and efficacy of Levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established. There are no data available. Add-on therapy for children (4 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg An oral solution is the preferred formulation for use in children under the age of 6 years. The initial therapeutic dose is 10 mg/kg twice daily. Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used. Dose in children 50 kg or greater is the same as in adults. <img src="/TGIF/Epivon-Table2.png" alt="Epivon Dosage Table 2" /> Infants and children less than 4 years There are insufficient data to recommend the use of Epivon in children under 4 years of age. Method of administration The film-coated tablets must be taken orally, swallowed with a sufficient quantity of liquid and may be taken with or without food. The daily dose is administered in two equally divided doses.
Route Of Administration: ORAL
Indication Info: 4.1 Therapeutic indications Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. Levetiracetam is indicated as adjunctive therapy <ul> <li>in the treatment of partial onset seizures with or without secondary generalisation in adults, and children from 4 years of age with epilepsy.</li> <li>in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</li> <li>in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.</li> </ul>
Contraindications: 4.3 Contraindications Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients.
Atc Code: N03AX14
Atc Item Name: levetiracetam
Pharma Manufacturer Name: NOVEM PHARMA PRIVATE LIMITED

Active Ingredients

Levetiracetam (Micronized)

1000mg

LEVETIRACETAM (MICRONIZED)

1,000 MG

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Nov 29, 2013

Approval ID

286cc768eefcee5b

Type

Therapeutic

Back to HSA Approvals